Caligiuri MA - Search Results

1

Diabetes mellitus induced by low-dose interleukin-2.

Soni N, Meropol NJ, Porter M, Caligiuri MA. Soni N, et al. Among authors: caligiuri ma. Cancer Immunol Immunother. 1996 Sep;43(1):59-62. doi: 10.1007/s002620050304. Cancer Immunol Immunother. 1996. PMID: 8917637

2

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.

Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perillo D, et al. Caligiuri MA, et al. J Clin Oncol. 1991 Dec;9(12):2110-9. doi: 10.1200/JCO.1991.9.12.2110. J Clin Oncol. 1991. PMID: 1960552

3

Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.

Bernstein ZP, Porter MM, Gould M, Lipman B, Bluman EM, Stewart CC, Hewitt RG, Fyfe G, Poiesz B, Caligiuri MA. Bernstein ZP, et al. Among authors: caligiuri ma. Blood. 1995 Nov 1;86(9):3287-94. Blood. 1995. PMID: 7579429 Free article. Clinical Trial.

4

Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes.

Baiocchi RA, Caligiuri MA. Baiocchi RA, et al. Among authors: caligiuri ma. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5577-81. doi: 10.1073/pnas.91.12.5577. Proc Natl Acad Sci U S A. 1994. PMID: 7911241 Free PMC article.

5

Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications.

Caligiuri MA. Caligiuri MA. Semin Oncol. 1993 Dec;20(6 Suppl 9):3-10. Semin Oncol. 1993. PMID: 8284689 Review.

6

CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.

Carson WE, Fehniger TA, Caligiuri MA. Carson WE, et al. Among authors: caligiuri ma. Eur J Immunol. 1997 Feb;27(2):354-60. doi: 10.1002/eji.1830270203. Eur J Immunol. 1997. PMID: 9045904

7

Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer.

Khatri VP, Baiocchi RA, Bernstein ZP, Caligiuri MA. Khatri VP, et al. Among authors: caligiuri ma. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S129-36. Cancer J Sci Am. 1997. PMID: 9457408 Review.

8

Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.

Khatri VP, Fehniger TA, Baiocchi RA, Yu F, Shah MH, Schiller DS, Gould M, Gazzinelli RT, Bernstein ZP, Caligiuri MA. Khatri VP, et al. Among authors: caligiuri ma. J Clin Invest. 1998 Mar 15;101(6):1373-8. doi: 10.1172/JCI2038. J Clin Invest. 1998. PMID: 9502779 Free PMC article.

9

A review of the association between interleukin-10 and human B-cell malignancies.

Khatri VP, Caligiuri MA. Khatri VP, et al. Among authors: caligiuri ma. Cancer Immunol Immunother. 1998 Jul;46(5):239-44. doi: 10.1007/s002620050483. Cancer Immunol Immunother. 1998. PMID: 9690451 Free PMC article. Review. No abstract available.

10

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA. Meropol NJ, et al. Among authors: caligiuri ma. Cancer Immunol Immunother. 1998 Aug;46(6):318-26. doi: 10.1007/s002620050493. Cancer Immunol Immunother. 1998. PMID: 9756416 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

484 results

Search Page

Filters